Kraig Biocraft Laboratories Reports Signing Landmark Agreements in South East Asia
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), announces today that...
Day: April 29, 2024
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in...
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines,...
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to...
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the...
FibroGen to Report First Quarter 2024 Financial Results
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on...
Breckenridge Brewery Introduces New West Coast Style IPA ‘Ridge Runner’
The Perfect Beer for Toasting The Trail Less TraveledLITTLETON, Colo., April 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brew”)...
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted...
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent...
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop...
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024...
CloudMD Announces Late Filing of Annual Financial Statements
TORONTO, April 29, 2024 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH) (the “Company”...
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients...
Delota Expands Product Line with Addition of Nicotine-Based Siberia White Snus Pouches
Vaughan, Ontario--(Newsfile Corp. - April 29, 2024) - Delota Corp. (CSE: NIC) (FSE: S62) ("Delota" or the "Company") a leading...
Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
LONDON, UK / ACCESSWIRE / April 29, 2024 / TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS...